NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
November 18, 2008 • Volume 5 / Number 23 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

New Drug for Patients with Advanced Thyroid Cancer

Name of the Trial
Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients with Inoperable Locoregionally Advanced or Metastatic Medullary or Differentiated Thyroid Carcinoma. See the protocol summary at http://www.cancer.gov/clinicaltrials/MAYO-MC0476.

Principal Investigators
Dr. Jeffrey Moley, Washington University in St. Louis, and Dr. Robert Smallridge, Mayo
Clinic Cancer Center

Special Issue on Cancer Imaging

Don't miss our December 2 special issue on cancer imaging, highlighting work by NCI staff and extramural grantees in this area, including the development of new technology and imaging agents, as well as research on their effectiveness in "the real world." NCI Cancer Bulletin special issues are some of the most popular among our readers. Past special issues have focused on cancer survivorship, pediatric oncology, and drug development.

Why This Trial Is Important
Most thyroid gland cancers, including follicular and papillary carcinomas, are well differentiated, slow growing, and highly treatable, often by administering radioactive iodine131 both before and after surgery to remove the thyroid. However, some of these differentiated tumors eventually stop taking up iodine, start behaving aggressively, and metastasize. Medullary thyroid cancers (MTC) arise from a different type of thyroid cell and are generally more aggressive. Many patients with MTC will see their cancer return and metastasize after initial treatment.

Surgery is the only curative treatment for most patients with iodine-resistant differentiated thyroid cancer or MTC. Some patients, however, have tumors that cannot be surgically removed (unresectable), and, in other patients, cancer cells have spread to lymph nodes in the neck or to distant sites, such as the lungs, liver, or bones. No effective treatment has been found for these patients, and new treatments are needed.

In this phase II trial, researchers are studying the effects of treatment with 17-AAG, an antitumor antibiotic drug that targets a protein called heat shock protein 90 (HSP90). Many proteins implicated in cancer development need HSP90, a member of a class of proteins called molecular chaperones, to help them achieve their correct functional shape and cellular location. Cancer cells often contain higher levels of HSP90 than normal cells, helping them to grow uncontrollably. In laboratory experiments with MTC, papillary and follicular thyroid carcinomas, and other cancer types, 17-AAG has proven effective in inhibiting cancer cell growth by interfering with the chaperone function of HSP90.

"While most thyroid cancers are very slow-growing and survival rates can be good at 15 years or longer, this trial is for that subset of patients with aggressively metastatic disease," said Dr. Moley. "These patients face a difficult challenge, and there haven't been many trials mounted to address their plight."

For More Information
See the lists of entry criteria and trial contact information at http://www.cancer.gov/clinicaltrials/MAYO-MC0476 or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll free and confidential.


An archive of "Featured Clinical Trial" columns is available at http://www.cancer.gov/clinicaltrials/ft-all-featured-trials.